Injectable Hydrogel Targeted Glioblastoma in 2026
Researchers developed a localized hydrogel treatment that disrupted tumor-promoting synapses in mice.
Updated on Oct. 2, 2026 in Cancer
Live Poll
Do you believe current advances in cancer neuroscience will lead to effective new patient treatments?
In 2026, scientists successfully tested an injectable hydrogel, HPAC-siNTRK2@Gel, designed to inhibit glioma growth by blocking synaptic inputs. The treatment reduced tumor recurrence and improved survival in mouse models without impacting normal behavioral function.
Why it matters
Glioma growth is frequently supported by synaptic inputs from surrounding neurons, a process that is difficult to disrupt without damaging healthy brain tissue. This approach addresses that challenge by specifically targeting the Ntrk2 gene at the site of tumor resection.
The HPAC-siNTRK2@Gel hydrogel was used in preclinical mouse models to target Ntrk2, which encodes the BDNF receptor TrkB. The treatment successfully potentiated the effects of chemoradiotherapy while preserving normal mouse behavioral function.
The players
Nature Biomedical Engineering
This is a peer-reviewed scientific journal that focuses on the integration of engineering and biomedical sciences to address human health challenges.
The details
The treatment is administered locally at the site where a brain tumor is surgically removed to interfere with synapses post-operatively. By disrupting the communication between neurons and glioblastoma cells, the hydrogel prevents the tumor from utilizing synaptic signals for its continued growth.
Timeline
The research paper was published in 2026.
The Big Picture
This development represents a significant step in the field of cancer neuroscience, moving toward therapies that decouple malignant cells from the host environment. It illustrates a transition from systemic drug delivery to site-specific neurological interventions in oncology.
This research provides a potential future framework for preventing glioblastoma recurrence through targeted post-surgical therapy. If successfully translated, it could eventually offer patients a way to improve survival outcomes without the behavioral side effects associated with systemic drugs.
The takeaway
The successful use of a local hydrogel to block tumor synapses suggests that the brain's own signaling pathways can be leveraged to inhibit cancer progression. This strategy demonstrates that surgical sites can serve as specialized zones for localized gene therapy.
Further reading
For more information on the latest advancements in oncology, visit the Cancer section.
More information
Read the detailed Nature Biomedical Engineering research paper for a complete analysis of the study.
Source note: This article includes information reported by Nature.
Live Poll
Do you believe current advances in cancer neuroscience will lead to effective new patient treatments?
